Among novel biomarkers of kidney function, most clinical studies about aminoglycoside AKI have been focused on urinary KIM-1, urinary beta-2 microglobulin, serum as well as urinary cystatin C, urinary monocyte chemoattractant protein-1, urinary IL-18, urinary NGAL, urinary NAG, and urinary TIMP2-IGFBP7 [3,42,78,161,162]. Here, LCN2 is linked to acute kidney injury.